changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact firstname.lastname@example.org
An open-label, prospective, multicenter, randomized, Phase III clinical trial evaluating yttrium-90 transarterial radioembolisation (TheraSphere™) in the treatment of patients with unresectable hepatocellular carcinoma (HCC).27,28
TheraSphere™ prior to initiation of standard-of-care therapy: sorafenib
Standard-of-care therapy: sorafenib
To evaluate the efficacy and safety of TheraSphere™ in patients with unresectable HCC in whom treatment with sorafenib is planned.
Primary: Overall survival
Secondary: Time to progression, tumour response, time to symptomatic progression, quality of life (FACT-hep), time to untreatable progression, safety
Please visit the THERASPHERE TRIALS WEBSITE for more details
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com